抗TNFα治疗持续时间影响炎症性肠病患者的反应丧失
该多中心回顾性队列研究纳入708例IBD患者的844个抗TNFα治疗疗程,发现反应丧失发生率随治疗时间延长而降低,治疗第一年反应丧失发生率是四年后的三倍。持续获益2年以上的患者后续反应丧失风险较低。
要点
- 抗TNFα治疗第一年反应丧失发生率为17.2%/患者年,四年后降至4.8%/患者年
- 持续获益2年以上的患者后续反应丧失风险较低
- 溃疡性结肠炎、CD狭窄或穿透性疾病是反应丧失的预测因素
核心结论
- 抗TNFα治疗持续2年以上仍获益的患者,后续反应丧失风险较低。
研究设计与样本
- 多中心回顾性队列研究,纳入2011-2019年间接受抗TNFα治疗至少4个月的UC或CD患者,共844个治疗疗程(708例患者),采用参数生存模型分析反应丧失发生率与治疗时间的关系,Cox回归识别预测因素。
主要发现
- 211个(25.0%)疗程发生反应丧失,其中66例(31.3%)检出抗药物抗体。
- 治疗第一年反应丧失发生率为17.2%/患者年,四年后为4.8%/患者年(P < 0.001)。
- 抗TNFα停药率从第一年28.6%/患者年降至四年后14.0%/患者年(P < 0.001),剂量递增率从38.0%/患者年降至6.8%/患者年(P < 0.001)。
- 反应丧失预测因素包括UC(vs CD,aHR 1.53,95% CI 1.10-2.15);CD患者中狭窄或穿透性疾病(aHR 1.68,95% CI 1.15-2.46)和男性(aHR 0.55,95% CI 0.38-0.78)。
- 免疫调节剂对伴抗药物抗体的反应丧失有保护作用(aHR 0.42,95% CI 0.24-0.74)。
临床怎么用
- 对于持续抗TNFα治疗2年以上仍应答良好的IBD患者,可考虑降低监测强度,后续反应丧失风险较低。
- UC患者及CD狭窄或穿透性疾病患者反应丧失风险较高,需加强监测。
- 联用免疫调节剂可能降低伴抗药物抗体患者的反应丧失风险。
局限性
- 回顾性研究设计可能存在选择偏倚和信息偏倚。
- 未报告全部潜在混杂因素的调整情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α therapy (anti-TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%-21% per patient-year). AIMS: To assess whether the incidence of loss of response decreases with longer treatment duration METHODS: This was a multicentre, retrospective cohort study of patients with ulcerative colitis (UC) or Crohn's disease (CD) who received anti-TNFα for at least 4 months between 2011 and 2019. We studied the incidence of loss of response as a function of treatment duration, employing parametric survival modelling. Predictors of loss of response were identified by Cox regression analysis. Secondary outcomes included overall anti-TNFα discontinuation and dose escalation. RESULTS: We included 844 anti-TNFα treatment episodes in 708 individuals. Loss of response occurred in 211 (25.0%) episodes, with anti-drug antibodies detected in 66 (31.3%). During the first year, the incidence of loss of response was three-fold higher than after four years of treatment (17.2% vs 4.8% per patient-year, P < 0.001). The incidence of anti-TNFα discontinuation (28.6% vs 14.0% per patient-year, P < 0.001) and dose escalations (38.0% vs 6.8% per patient-year, P < 0.001) also decreased significantly from the first year to after four years, respectively. Predictors of loss of response included UC (vs CD, adjusted hazard ratio [aHR] 1.53, 95% CI 1.10-2.15) and, among patients with CD, stricturing or penetrating disease (aHR 1.68, 95% CI 1.15-2.46) and male sex (aHR 0.55, 95% CI 0.38-0.78). Immunomodulators were protective against loss of response with anti-drug antibodies (aHR 0.42, 95% CI 0.24-0.74). CONCLUSIONS: Patients with sustained benefit to anti-TNFα after 2 years are at low risk of subsequent loss of response.
引用
- Schultheiss JPD, Mahmoud R, Louwers JM, et al. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2021. PMID: 34559428. doi:10.1111/apt.16605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。